{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T23:42:25Z","timestamp":1770766945029,"version":"3.50.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Yang Liang","award":["201603"],"award-info":[{"award-number":["201603"]}]},{"name":"Hua Wang","award":["81700148"],"award-info":[{"award-number":["81700148"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-12880-9","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T19:02:20Z","timestamp":1725908540000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma"],"prefix":"10.1186","volume":"24","author":[{"given":"Dong","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenrui","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Demei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanjun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,9]]},"reference":[{"issue":"5","key":"12880_CR1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464\u201377. https:\/\/doi.org\/10.1001\/jama.2022.0003.","journal-title":"JAMA"},{"issue":"17","key":"12880_CR2","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1200\/JCO.19.02515","volume":"38","author":"NS Joseph","year":"2020","unstructured":"Joseph NS, Kaufman JL, Dhodapkar MV, et al. Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol. 2020;38(17):1928\u201337. https:\/\/doi.org\/10.1200\/JCO.19.02515.","journal-title":"J Clin Oncol"},{"issue":"2","key":"12880_CR3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0277-5379(89)90001-1","volume":"25","author":"DE Bergsagel","year":"1989","unstructured":"Bergsagel DE. Is aggressive chemotherapy more effective in the treatment of plasma cell myeloma? Eur J Cancer Clin Oncol. 1989;25(2):159\u201361. https:\/\/doi.org\/10.1016\/0277-5379(89)90001-1.","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"5","key":"12880_CR4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","volume":"116","author":"PG Richardson","year":"2010","unstructured":"Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. J Am Soc Hematol Blood. 2010;116(5):679\u201386. https:\/\/doi.org\/10.1182\/blood-2010-02-268862.","journal-title":"J Am Soc Hematol Blood"},{"issue":"16","key":"12880_CR5","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1182\/blood.2019000241","volume":"134","author":"L Rosi\u00f1ol","year":"2019","unstructured":"Rosi\u00f1ol L, Oriol A, Rios R, et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. J Am Soc Hematol Blood. 2019;134(16):1337\u201345. https:\/\/doi.org\/10.1182\/blood.2019000241.","journal-title":"J Am Soc Hematol Blood"},{"issue":"5","key":"12880_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","volume":"10","author":"BGM Durie","year":"2020","unstructured":"Durie BGM, Hoering A, Sexton R, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020;10(5):53. https:\/\/doi.org\/10.1038\/s41408-020-0311-8.","journal-title":"Blood Cancer J"},{"issue":"10068","key":"12880_CR7","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BGM Durie","year":"2017","unstructured":"Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389(10068):519\u201327. https:\/\/doi.org\/10.1016\/S0140-6736(16)31594-X.","journal-title":"Lancet"},{"issue":"24","key":"12880_CR8","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","volume":"30","author":"P Sonneveld","year":"2012","unstructured":"Sonneveld P, Schmidt-Wolf IGH, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/GMMG-HD4 trial. J Clin Oncol. 2012;30(24):2946\u201355. https:\/\/doi.org\/10.1200\/JCO.2011.39.6820.","journal-title":"J Clin Oncol"},{"issue":"8","key":"12880_CR9","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1038\/leu.2015.80","volume":"29","author":"EK Mai","year":"2015","unstructured":"Mai EK, Bertsch U, D\u00fcrig J, et al. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia. 2015;29(8):1721\u20139. https:\/\/doi.org\/10.1038\/leu.2015.80.","journal-title":"Leukemia"},{"issue":"4","key":"12880_CR10","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/j.1365-2141.2008.06997.x","volume":"141","author":"R Popat","year":"2008","unstructured":"Popat R, Oakervee HE, Hallam S, et al. Bortezomib, doxorubicin and dexamethasone (PAD) frontline treatment of multiple myeloma: updated results after long-term follow\u2010up. Br J Haematol. 2008;141(4):512\u20136. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.06997.x.","journal-title":"Br J Haematol"},{"issue":"2","key":"12880_CR11","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00432-013-1570-6","volume":"140","author":"BT Huang","year":"2014","unstructured":"Huang BT, Tan Y, Zhao WH, et al. How to determine bortezomib-based regimen for elderly patients with multiple myeloma: PAD versus CBd, an observational study. J Cancer Res Clin Oncol. 2014;140(2):303\u20139. https:\/\/doi.org\/10.1007\/s00432-013-1570-6.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"8","key":"12880_CR12","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6.","journal-title":"Lancet Oncol"},{"issue":"1","key":"12880_CR13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41375-020-01012-4","volume":"35","author":"LJ Costa","year":"2021","unstructured":"Costa LJ, Derman BA, Bal S, et al. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia. 2021;35(1):18\u201330. https:\/\/doi.org\/10.1038\/s41375-020-01012-4.","journal-title":"Leukemia"},{"issue":"6","key":"12880_CR14","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","volume":"32","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Rajkumar SV, San Miguel JF, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014;32(6):587\u2013600. https:\/\/doi.org\/10.1200\/JCO.2013.48.7934.","journal-title":"J Clin Oncol"},{"issue":"12","key":"12880_CR15","doi-asserted-by":"publisher","first-page":"e540","DOI":"10.1016\/S1470-2045(20)30635-5","volume":"21","author":"O Landgren","year":"2020","unstructured":"Landgren O, Siegel D, Kazandjian D, Costa L, Jakubowiak A. Treatments for newly diagnosed multiple myeloma: when endurance is interrupted. Lancet Oncol. 2020;21(12):e540. https:\/\/doi.org\/10.1016\/S1470-2045(20)30635-5.","journal-title":"Lancet Oncol"},{"issue":"14","key":"12880_CR16","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376(14):1311\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1611750.","journal-title":"N Engl J Med"},{"issue":"11","key":"12880_CR17","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41408-018-0147-7","volume":"8","author":"MH Sidiqi","year":"2018","unstructured":"Sidiqi MH, Aljama MA, Bin Riaz I, et al. Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. Blood Cancer J. 2018;8(11):106. https:\/\/doi.org\/10.1038\/s41408-018-0147-7.","journal-title":"Blood Cancer J"},{"issue":"4","key":"12880_CR18","doi-asserted-by":"publisher","first-page":"863","DOI":"10.3390\/cancers13040863","volume":"13","author":"S Devarakonda","year":"2021","unstructured":"Devarakonda S, Efebera Y, Sharma N. Role of stem cell transplantation in multiple myeloma. Cancers. 2021;13(4):863. https:\/\/doi.org\/10.3390\/cancers13040863.","journal-title":"Cancers"},{"key":"12880_CR19","doi-asserted-by":"publisher","first-page":"101929","DOI":"10.1016\/j.ctrv.2019.101929","volume":"82","author":"I Ntanasis-Stathopoulos","year":"2020","unstructured":"Ntanasis-Stathopoulos I, Gavriatopoulou M, Kastritis E, Terpos E, Dimopoulos MA. Multiple myeloma: role of autologous transplantation. Cancer Treat Rev. 2020;82:101929. https:\/\/doi.org\/10.1016\/j.ctrv.2019.101929.","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"12880_CR20","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1182\/blood-2011-01-332320","volume":"118","author":"J Martinez-Lopez","year":"2011","unstructured":"Martinez-Lopez J, Blade J, Mateos MV, et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. J Am Soc Hematol Blood. 2011;118(3):529\u201334. https:\/\/doi.org\/10.1182\/blood-2011-01-332320.","journal-title":"J Am Soc Hematol Blood"},{"issue":"5","key":"12880_CR21","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/ajh.26491","volume":"97","author":"P O\u2019Gorman","year":"2022","unstructured":"O\u2019Gorman P, Laubach JP, O\u2019Dwyer ME, et al. Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma. Am J Hematol. 2022;97(5):562\u201373. https:\/\/doi.org\/10.1002\/ajh.26491.","journal-title":"Am J Hematol"},{"issue":"4","key":"12880_CR22","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma[J]. N Engl J Med. 2024;390(4):301\u201313. https:\/\/doi.org\/10.1056\/NEJMoa2312054.","journal-title":"N Engl J Med"},{"issue":"8","key":"12880_CR23","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial[J]. Blood J Am Soc Hematol. 2020;136(8):936\u201345. https:\/\/doi.org\/10.1182\/blood.2020005288.","journal-title":"Blood J Am Soc Hematol"},{"issue":"4","key":"12880_CR24","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","volume":"36","author":"T Facon","year":"2022","unstructured":"Facon T, Cook G, Usmani SZ, et al. Daratumumab plus Lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA[J]. Leukemia. 2022;36(4):1066\u201377. https:\/\/doi.org\/10.1038\/s41375-021-01488-8.","journal-title":"Leukemia"},{"key":"12880_CR25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400712","author":"T Facon","year":"2024","unstructured":"Facon T, Dimopoulos MA, Leleu XP, et al. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for multiple myeloma. NEW ENGL J MED. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2400712.","journal-title":"NEW ENGL J MED"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12880-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12880-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12880-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T19:03:52Z","timestamp":1725908632000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12880-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,9]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12880"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12880-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,9]]},"assertion":[{"value":"25 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Institutional Ethical Review Board of Sun Yat-Sen university cancer center. Informed consent requirements were also waived by Institutional Ethical Review Board of Sun Yat-Sen university cancer center. The International Conference on Harmonization\u2019s Good Clinical Practice standards and the 1964 Helsinki Declaration and its later revisions served as the foundation for the study\u2019s methodology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1123"}}